The British Medicines and Healthcare products Regulatory Agency (MHRA) has expanded approval for the gene therapy Casgevy (exagamglogene autotemcel), making it available to children aged five and above. The drug is designed to treat patients with severe sickle cell disease and transfusion-dependent beta-thalassemia — inherited blood disorders that previously required lifelong medical intervention, including regular blood transfusions. Casgevy is based on CRISPR/Cas9 gene-editing technology and represents one of the first approved treatments worldwide using this technology. The therapy works by modifying the patient's own stem cells, enabling the body to produce functional hemoglobin and reducing or eliminating disease symptoms. Previously, the drug was available only to adult patients in the United Kingdom. The expansion of age eligibility will allow more children with severe forms of these disorders to access potentially curative therapy at an earlier stage of life, which could significantly improve their long-term health prospects and quality of life. Sickle cell disease and beta-thalassemia are among the most common inherited blood disorders worldwide, affecting millions of people, particularly in regions of Africa, the Middle East, and South Asia. The MHRA's decision is viewed as an important step in advancing gene medicine and expanding access to innovative treatment methods for vulnerable patient groups, including children.